Cancer Nanomedicine and Immune System—Interactions and Challenges
Autor: | Suhana Ahmad, Ros Akmal Mohd Idris, Wan Nurhidayah Wan Hanaffi, Komathi Perumal, Jennifer C. Boer, Magdalena Plebanski, Juhana Jaafar, Jit Kang Lim, Rohimah Mohamud |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Drug media_common.quotation_subject TP1-1185 immunogenicity Bioinformatics 03 medical and health sciences 0302 clinical medicine Immune system Medicine Drug toxicity media_common Tumor microenvironment tumor micoenvironment business.industry Chemical technology Cancer medicine.disease drug development 030104 developmental biology Drug development 030220 oncology & carcinogenesis Drug delivery Nanomedicine cytotoxicity hypersensitivity business |
Zdroj: | Frontiers in Nanotechnology, Vol 3 (2021) |
ISSN: | 2673-3013 |
DOI: | 10.3389/fnano.2021.681305/full |
Popis: | Nanoparticles have tremendous therapeutic potential in the treatment of cancer as they increase drug delivery, attenuate drug toxicity, and protect drugs from rapid clearance. Since Doxil®, the first FDA-approved nanomedicine, several other cancer nanomedicines have been approved and have successfully increased the efficacy over their free drug counterparts. Although their mechanisms of action are well established, their effects towards our immune system, particularly in the tumor microenvironment (TME), still warrant further investigation. Herein, we review the interactions between an approved cancer nanomedicine with TME immunology. We also discuss the challenges that need to be addressed for the full clinical potential of ongoing cancer nanomedicines despite the encouraging preclinical data. |
Databáze: | OpenAIRE |
Externí odkaz: |